Opaleye Management’s Trevi Therapeutics TRVI Stock Holding History

Opaleye Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.12M	Hold	345,100	–	–	0.54%	35
2025 Q4	$4.32M	Sell	345,100 -44,900	-12%	-$519K	0.57%	35
2025 Q3	$3.57M	Hold	390,000	–	–	0.5%	31
2025 Q2	$2.13M	Sell	390,000 -405,000	-51%	-$2.52M	0.43%	34
2025 Q1	$5M	Sell	795,000 -1,522,500	-66%	-$7.26M	1.11%	18
2024 Q4	$9.55M	Sell	2,317,500 -250,490	-10%	-$802K	1.67%	14
2024 Q3	$8.58M	Sell	2,567,990 -77,010	-3%	-$229K	1.43%	17
2024 Q2	$7.88M	Hold	2,645,000	–	–	1.8%	15
2024 Q1	$9.13M	Buy	2,645,000 +110,000	+4%	+$245K	1.99%	18
2023 Q4	$3.4M	Buy	2,535,000 +829,100	+49%	+$1.26M	0.9%	27
2023 Q3	$3.72M	Buy	1,705,900 +4,400	+0.3%	+$9.94K	1.21%	24
2023 Q2	$4.07M	Buy	1,701,500 +865,700	+104%	+$2.18M	0.97%	27
2023 Q1	$1.55M	Buy	835,800 +350,800	+72%	+$794K	0.46%	38
2022 Q4	$936K	Buy	+485,000	New	+$956K	0.33%	39

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Opaleye Management's TRVI Position: Q1 2026 in Review

Opaleye Management held its Trevi Therapeutics (TRVI) position steady in Q1 2026 at 345,100 shares worth $4.12M. The position accounts for 0.54% of the portfolio, ranked #35.

Opaleye Management first reported a position in TRVI in Q4 2022 and has held it in 14 quarters since. The position peaked at $9.55M in Q4 2024. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Opaleye Management held 345,100 shares of Trevi Therapeutics worth $4.12M as of Q1 2026.
Opaleye Management left its Trevi Therapeutics share count unchanged in Q1 2026.
Trevi Therapeutics made up 0.54% of Opaleye Management's portfolio in Q1 2026, its #35 holding.
Opaleye Management first reported a position in Trevi Therapeutics in Q4 2022 and has held it in 14 quarters since.
Opaleye Management's Trevi Therapeutics position peaked at $9.55M in Q4 2024.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.